Expert insights. Personalized for you.
The results are a boost for Lilly's drug, tirzepatide, which is being prepared for regulatory submissions later this year. But long-term heart data won't be available for some time MORE
Initial results from a mid-stage study indicate the antiviral drug, molnupiravir, is safe. But whether it's hitting the study's main goal remains unclear MORE
Trodelvy, a key drug for Gilead's ambitions in oncology, is now fully approved to treat an aggressive, hard-to-treat form of breast cancer MORE
This translates to longer development times for cancer drugs which means that cancer patients could suffer. It’s essential that drug companies get creative and find new ways to reach patients when incomes to cancer drug screening and clinical trials. MORE
Results from a mid-stage study showed Amgen's drug, sotorasib, shrank tumors in over a third of lung cancer patients, affirming earlier findings MORE
According to Acadia, the FDA took issue with the main study used in its drug approval submission. That surprised the company, since regulators had never seemed concerned with the study's design MORE
SUMMARY: Democratic lawmakers are weighing whether to include drug pricing measures that could extract tens of billions of dollars from the industry. We’re just not sure when,” said one drug industry lobbying source. The drug industry has had a large target on its back for a long time. MORE
The deal for Rodeo Therapeutics follows closely on the heels of the large biotech's buyout of cancer drug developer Five Prime MORE
Another TED talk on the evils of prescription drug marketing was filled with misinformation as usual. The disconnect between consumers and prescription drug marketing has grown quite a bit. The post Prescription drug marketing misconceptions appeared first on World of DTC Marketing.com. MORE
Though a mid-stage study read out negative, Neurocrine still sees a path forward for the drug, which it licensed from Takeda last summer MORE
The drug, now known as Oxlumo, is the first approved treatment for patients with a potentially life-threatening condition that can cause kidney failure. Like other Alnylam drugs, it comes at a six-figure list price MORE
Average list price increases across the drug industry, however, appear lower than last year, according to one analysis MORE
online pharmacy that actually tests the quality of medication it sends to patients and apparently, to my delight, they support drug importation as a policy to lower costs. Food and Drug Administration to make sure those drugs will work as directed by their prescribers. MORE
Biologic drugs rack up billions in annual U.S. Drugs (Pharmaceuticals) Biotechnology and Bioengineering Humira (Drug) Prices (Fares, Fees and Rates) Law and Legislation Inventions and Patents Generic Brands and Productssales. Here’s a solution to lower the costs. MORE
SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. Drug Prices MORE
QUICK READ: A two-month analysis of social media and prescription drugs found the number one reason online health seekers use social media is to share and ask questions about medication side effects. The post <strong>Social media and prescription drugs:</strong> A study. MORE
A large safety study found that patients given Pfizer's Xeljanz had health issues like major heart complications and cancer at a higher rate than those who got a different kind of anti-inflammation drug MORE
In a new editorial, three of the agency's advisers reiterated that they see "no persuasive evidence to support approval of aducanumab at this time " MORE
The decision to end development of a medicine acquired in a $425 million deal last November is another disappointment for Merck's coronavirus effort, which once involved multiple drugs and vaccines MORE
Meanwhile, the drug has also caught the attention of a powerful cost watchdog group On Nov. 6, aducanumab will go before a panel of experts who will review it and make recommendations to the FDA. MORE
The news this week that Amazon.com is getting into the prescription drug business sent stocks of retail pharmacies down but questions sell remain. This week, Amazon’s news that they are finally leaping into the prescription drug business was not a shock. MORE
The request comes less than six months after the FDA authorized Lilly's bamlanivimab, reflecting the spread of virus variants that can elude the drug MORE
A casual party drug endures. Drug Abuse and Traffic Drugs (Pharmaceuticals) Hsieh, Tony Addiction (Psychology) WhippetsHippie crack. Whippets. Laughing gas. MORE
QUICK READ : Prescribers are reviewing some of their favorite prescribed drugs and are open to learning about new drugs in terms of efficacy and patient outcomes but you had better be ready to talk about patients beyond the science. MORE
The $85 million acquisition is an unusual and early step for a company like Relay, which went public last July and only just began clinical testing of its lead drugs last year MORE
Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests MORE
The NIH stopped enrolling patients hospitalized with coronavirus disease into a study of Vir's antibody drug after data monitors questioned its effectiveness MORE
Two drugs developed by Wave Life Sciences didn't appear to have an effect on disease-causing proteins, another setback for Huntington's research after disappointing results last week from Roche and Ionis MORE
A disappointing recommendation from outside data reviewers raises doubts about the DNA-targeting drug's benefits and puts pressure on Roche's partner, Ionis Pharmaceuticals MORE
The setback follows disappointing results from companies like Novartis and Sanofi, which have also sought to repurpose existing drugs for COVID-19 MORE
The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact MORE
In a landmark study, fewer people given Ebanga died from Ebola virus infection than did those who received a control drug. Results from the trial also led to an OK for Regeneron's drug Inmazeb MORE
Negative results for the experimental drug semorinemab dents a theory that Alzheimer's disease may be caused by tangles of the protein tau in the brain MORE
By teaming up with Sage, Biogen gets its hands on two drugs in mid- to late-stage testing for multiple types of depression and essential tremor MORE
Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19 MORE
New results from an WHO study, however, raise questions about the drug's ultimate effectiveness The U.S. regulator granted a full approval after allowing emergency use earlier this year. MORE
Study results presented at AACR showed Retevmo shrank tumors in nine different cancers, building a case for the type of tissue-agnostic label that only three other medicines have secured MORE
If approved, TG's drug would join Roche's fast-selling Ocrevus and Novartis' newer entrant Kesimpta as one of a newer class of multiple sclerosis therapies MORE
Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround MORE
While the biotech prepares to launch aducanumab, its latest earnings report shows significant hits to top-selling drugs, plus another pipeline failure MORE
Lupkynis, the first oral drug approved for lupus nephritis, comes with a high list price. Its developer, Aurinia Pharmaceuticals, expects average net revenue of roughly $65,000 per patient per year MORE
SUMMARY: Per the Times, “what if consumers could calculate the benefits and risks of taking a prescription drug as easily as they can gauge the carbohydrates and calories in an Oreo cookie?” ” Drug facts boxes are needed, but the FDA disagrees. A Drug Facts Box? MORE
Amlodipine is one of the most commonly prescribed drugs in the UK and the most prescribed high blood pressure ( BP ) medication. When patients are diagnosed with high blood pressure and a drug is recommended, amlodipine may be the first choice, but not always. MORE
Elimination of the so-called penny rule in Medicaid could force drugmakers to pay larger rebates on a number of top medicines, including some HIV, diabetes and anti-inflammatory drugs MORE
Drugs Related Topics World of DTC Marketing
MARCH 23, 2021
SUMMARY: Democratic lawmakers are weighing whether to include drug pricing measures that could extract tens of billions of dollars from the industry. We’re just not sure when,” said one drug industry lobbying source. The drug industry has had a large target on its back for a long time.
World of DTC Marketing
DECEMBER 10, 2020
SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. Drug Prices
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
OCTOBER 6, 2020
This translates to longer development times for cancer drugs which means that cancer patients could suffer. It’s essential that drug companies get creative and find new ways to reach patients when incomes to cancer drug screening and clinical trials.
Bio Pharma Dive
MARCH 23, 2021
A disappointing recommendation from outside data reviewers raises doubts about the DNA-targeting drug's benefits and puts pressure on Roche's partner, Ionis Pharmaceuticals
World of DTC Marketing
APRIL 9, 2021
QUICK READ: A two-month analysis of social media and prescription drugs found the number one reason online health seekers use social media is to share and ask questions about medication side effects. The post <strong>Social media and prescription drugs:</strong> A study.
World of DTC Marketing
DECEMBER 3, 2020
Another TED talk on the evils of prescription drug marketing was filled with misinformation as usual. The disconnect between consumers and prescription drug marketing has grown quite a bit. The post Prescription drug marketing misconceptions appeared first on World of DTC Marketing.com.
Bio Pharma Dive
MARCH 8, 2021
Initial results from a mid-stage study indicate the antiviral drug, molnupiravir, is safe. But whether it's hitting the study's main goal remains unclear
Bio Pharma Dive
APRIL 16, 2021
The $85 million acquisition is an unusual and early step for a company like Relay, which went public last July and only just began clinical testing of its lead drugs last year
Bio Pharma Dive
APRIL 19, 2021
Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests
Bio Pharma Dive
MARCH 2, 2021
Though a mid-stage study read out negative, Neurocrine still sees a path forward for the drug, which it licensed from Takeda last summer
Bio Pharma Dive
MARCH 30, 2021
Two drugs developed by Wave Life Sciences didn't appear to have an effect on disease-causing proteins, another setback for Huntington's research after disappointing results last week from Roche and Ionis
World of DTC Marketing
JULY 23, 2020
QUICK READ : Prescribers are reviewing some of their favorite prescribed drugs and are open to learning about new drugs in terms of efficacy and patient outcomes but you had better be ready to talk about patients beyond the science.
Bio Pharma Dive
MARCH 4, 2021
The results are a boost for Lilly's drug, tirzepatide, which is being prepared for regulatory submissions later this year. But long-term heart data won't be available for some time
Bio Pharma Dive
DECEMBER 22, 2020
In a landmark study, fewer people given Ebanga died from Ebola virus infection than did those who received a control drug. Results from the trial also led to an OK for Regeneron's drug Inmazeb
Bio Pharma Dive
JANUARY 25, 2021
Lupkynis, the first oral drug approved for lupus nephritis, comes with a high list price. Its developer, Aurinia Pharmaceuticals, expects average net revenue of roughly $65,000 per patient per year
Bio Pharma Dive
JANUARY 28, 2021
Results from a mid-stage study showed Amgen's drug, sotorasib, shrank tumors in over a third of lung cancer patients, affirming earlier findings
Bio Pharma Dive
APRIL 5, 2021
According to Acadia, the FDA took issue with the main study used in its drug approval submission. That surprised the company, since regulators had never seemed concerned with the study's design
Bio Pharma Dive
NOVEMBER 24, 2020
The drug, now known as Oxlumo, is the first approved treatment for patients with a potentially life-threatening condition that can cause kidney failure. Like other Alnylam drugs, it comes at a six-figure list price
Druggist
APRIL 1, 2021
Amlodipine is one of the most commonly prescribed drugs in the UK and the most prescribed high blood pressure ( BP ) medication. When patients are diagnosed with high blood pressure and a drug is recommended, amlodipine may be the first choice, but not always.
Bio Pharma Dive
NOVEMBER 9, 2020
The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact
Bio Pharma Dive
APRIL 16, 2021
The request comes less than six months after the FDA authorized Lilly's bamlanivimab, reflecting the spread of virus variants that can elude the drug
Bio Pharma Dive
NOVEMBER 27, 2020
By teaming up with Sage, Biogen gets its hands on two drugs in mid- to late-stage testing for multiple types of depression and essential tremor
Pharmacy Checkers
SEPTEMBER 10, 2020
online pharmacy that actually tests the quality of medication it sends to patients and apparently, to my delight, they support drug importation as a policy to lower costs. Food and Drug Administration to make sure those drugs will work as directed by their prescribers.
Bio Pharma Dive
SEPTEMBER 29, 2020
Meanwhile, the drug has also caught the attention of a powerful cost watchdog group On Nov. 6, aducanumab will go before a panel of experts who will review it and make recommendations to the FDA.
Bio Pharma Dive
OCTOBER 22, 2020
New results from an WHO study, however, raise questions about the drug's ultimate effectiveness The U.S. regulator granted a full approval after allowing emergency use earlier this year.
NY Times
MARCH 15, 2021
Biologic drugs rack up billions in annual U.S. Drugs (Pharmaceuticals) Biotechnology and Bioengineering Humira (Drug) Prices (Fares, Fees and Rates) Law and Legislation Inventions and Patents Generic Brands and Productssales. Here’s a solution to lower the costs.
Bio Pharma Dive
NOVEMBER 12, 2020
The setback follows disappointing results from companies like Novartis and Sanofi, which have also sought to repurpose existing drugs for COVID-19
Bio Pharma Dive
NOVEMBER 5, 2020
Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround
World of DTC Marketing
NOVEMBER 19, 2020
The news this week that Amazon.com is getting into the prescription drug business sent stocks of retail pharmacies down but questions sell remain. This week, Amazon’s news that they are finally leaping into the prescription drug business was not a shock.
Bio Pharma Dive
APRIL 11, 2021
Study results presented at AACR showed Retevmo shrank tumors in nine different cancers, building a case for the type of tissue-agnostic label that only three other medicines have secured
Bio Pharma Dive
APRIL 8, 2021
Trodelvy, a key drug for Gilead's ambitions in oncology, is now fully approved to treat an aggressive, hard-to-treat form of breast cancer
NY Times
JANUARY 30, 2021
A casual party drug endures. Drug Abuse and Traffic Drugs (Pharmaceuticals) Hsieh, Tony Addiction (Psychology) WhippetsHippie crack. Whippets. Laughing gas.
Bio Pharma Dive
FEBRUARY 3, 2021
While the biotech prepares to launch aducanumab, its latest earnings report shows significant hits to top-selling drugs, plus another pipeline failure
Bio Pharma Dive
MARCH 3, 2021
The NIH stopped enrolling patients hospitalized with coronavirus disease into a study of Vir's antibody drug after data monitors questioned its effectiveness
World of DTC Marketing
FEBRUARY 25, 2021
SUMMARY: Per the Times, “what if consumers could calculate the benefits and risks of taking a prescription drug as easily as they can gauge the carbohydrates and calories in an Oreo cookie?” ” Drug facts boxes are needed, but the FDA disagrees. A Drug Facts Box?
Bio Pharma Dive
JANUARY 27, 2021
A large safety study found that patients given Pfizer's Xeljanz had health issues like major heart complications and cancer at a higher rate than those who got a different kind of anti-inflammation drug
Bio Pharma Dive
JANUARY 4, 2021
Average list price increases across the drug industry, however, appear lower than last year, according to one analysis
Bio Pharma Dive
OCTOBER 14, 2020
Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19
Bio Pharma Dive
SEPTEMBER 23, 2020
Negative results for the experimental drug semorinemab dents a theory that Alzheimer's disease may be caused by tangles of the protein tau in the brain
Bio Pharma Dive
APRIL 15, 2021
The decision to end development of a medicine acquired in a $425 million deal last November is another disappointment for Merck's coronavirus effort, which once involved multiple drugs and vaccines
Bio Pharma Dive
MARCH 31, 2021
The deal for Rodeo Therapeutics follows closely on the heels of the large biotech's buyout of cancer drug developer Five Prime
Bio Pharma Dive
MARCH 31, 2021
In a new editorial, three of the agency's advisers reiterated that they see "no persuasive evidence to support approval of aducanumab at this time "
Bio Pharma Dive
MARCH 12, 2021
Elimination of the so-called penny rule in Medicaid could force drugmakers to pay larger rebates on a number of top medicines, including some HIV, diabetes and anti-inflammatory drugs
229 
Let's personalize your content